Phoenix Biotechnology
Phoenix Biotechnology, Inc. is a Texas-based company specializing in the development of safe and effective natural products for the treatment of human and animal diseases. The company is committed to addressing unmet medical needs in cancer, viral diseases, neuroprotection, and neurodegenerative diseases, with a focus on making therapies widely available at low cost. Their research includes the development of therapies based on oleander extracts and cardiac glycosides, with ongoing clinical trials and preclinical studies demonstrating promising results.
Industries
Nr. of Employees
small (1-50)
Phoenix Biotechnology
San Antonio, Texas, United States
Patents
Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
US-11331291-B2
View Details
Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
US-11331291-B2
View DetailsProducts
Oleander-derived botanical extract for oncology
A supercritical CO2 botanical extract derived from Nerium oleander developed for evaluation in oncology indications; assessed in vitro and in vivo and in early-phase clinical trials.
Defined oleandrin-containing extract for antiviral research
A defined botanical extract containing cardiac glycoside constituents evaluated for antiviral prophylactic and therapeutic activity in vitro and in animal models.
PBI-01207
PBI-01207 is the primary active component of Anvirzel®, consisting of specific plant polysaccharides, triterpenes, and oleandrin, a key active ingredient with anticancer properties. It has been tested in vitro, in vivo, and in an FDA approved Phase I clinical study.
PBI-05204
An oleandrin-containing product developed by Phoenix Biotechnology that is selectively toxic to human malignant cells but not to normal cells, targeting multiple mechanisms of action in cancer therapy.
PBI-01011
A Nerium oleander extract based product by Phoenix Biotechnology, Inc. targeting viral infections with neuroprotective and neurodegenerative disease applications.
PBI-04711
A product without oleandrin and other cardiac glycosides that still provides significant neuroprotection from brain injury caused by neuroinflammation and oxidative injury. It crosses the blood brain barrier and has demonstrated neuroprotective activity in vitro.
Oleander-derived botanical extract for oncology
A supercritical CO2 botanical extract derived from Nerium oleander developed for evaluation in oncology indications; assessed in vitro and in vivo and in early-phase clinical trials.
Defined oleandrin-containing extract for antiviral research
A defined botanical extract containing cardiac glycoside constituents evaluated for antiviral prophylactic and therapeutic activity in vitro and in animal models.
PBI-01207
PBI-01207 is the primary active component of Anvirzel®, consisting of specific plant polysaccharides, triterpenes, and oleandrin, a key active ingredient with anticancer properties. It has been tested in vitro, in vivo, and in an FDA approved Phase I clinical study.
PBI-05204
An oleandrin-containing product developed by Phoenix Biotechnology that is selectively toxic to human malignant cells but not to normal cells, targeting multiple mechanisms of action in cancer therapy.
PBI-01011
A Nerium oleander extract based product by Phoenix Biotechnology, Inc. targeting viral infections with neuroprotective and neurodegenerative disease applications.
PBI-04711
A product without oleandrin and other cardiac glycosides that still provides significant neuroprotection from brain injury caused by neuroinflammation and oxidative injury. It crosses the blood brain barrier and has demonstrated neuroprotective activity in vitro.
Services
In vitro and in vivo evaluation of botanical-derived therapeutic candidates for anticancer and antiviral activity, including orthotopic tumor models and animal efficacy studies.
LC–MS/MS-based extract/component characterization and pharmacokinetic/metabolism studies in animal models.
In vitro assays to evaluate innate immune activation, NK cell and monocyte responses, and cytokine production under normal and challenged culture conditions.
Application of cost-effective machine learning algorithms to screen chemical libraries and prioritize candidates (e.g., for senolytic activity) for experimental validation.
Partnerships with academic centers and contract research organizations to extend preclinical testing, patient-derived tumor evaluation, and clinical trial operations.
In vitro and in vivo evaluation of botanical-derived therapeutic candidates for anticancer and antiviral activity, including orthotopic tumor models and animal efficacy studies.
LC–MS/MS-based extract/component characterization and pharmacokinetic/metabolism studies in animal models.
In vitro assays to evaluate innate immune activation, NK cell and monocyte responses, and cytokine production under normal and challenged culture conditions.
Application of cost-effective machine learning algorithms to screen chemical libraries and prioritize candidates (e.g., for senolytic activity) for experimental validation.
Partnerships with academic centers and contract research organizations to extend preclinical testing, patient-derived tumor evaluation, and clinical trial operations.
Expertise Areas
- Natural product drug development
- Preclinical pharmacology and toxicology
- Oncology drug development
- Antiviral therapeutics research
Key Technologies
- Supercritical CO2 extraction
- LC–MS/MS bioanalysis
- In vitro infectivity assays
- Orthotopic and xenograft animal tumor models